Treatment of prostate cancer by hypofractionated radiotherapy

Sefik IGDEM
426 211

Öz


Technological advances in radiation therapy delivery have
permitted the use of high dose per fraction radiotherapy for
early stage prostate cancer. Level I evidence supporting
the safety and efficasy of hypofractionated radiotherapy is
evolving. Moderate and extreme hypofractionation regimens
show promising cancer control but long term results of
noninferiority studies of both modalities are required before
use in routine treatment as standard of care.
Keywords: Prostate cancer, Curative radiotherapy,
Moderate and extreme hypo fractionation


Anahtar kelimeler


Prostate cancer, Curative radiotherapy, Moderate and extreme hypo fractionation

Tam metin:

PDF (English)


DOI: http://dx.doi.org/10.5472/mmj.11680

Referanslar


Dearnaley D, Syndikus I, Sumo G, et al. Conventional

versus hypofractionated high dose intensity modulated

radiotherapy for prostate cancer: preliminary safety

results from the CHHiP randomised control trial.

Lancet Oncol 2012;13:43-54. doi: 10.1016/S1470-

(11)70293-5.

Arcangeli G, Saracino B, Gomellini S, et al. A prospective

phase III randomised trial of hypofractination versus

conventional fractionation in patients with high

risk prostate cancer. Int J Radiat Oncol Biol Phys

;72:11-18. doi: 10.1016/j.ijrobp.2009.07.1691.

Arcangeli G, Strigari L, Gomellini S, et al. Updated

results and patterns of failure in a randomized

hypofractionation trial for high risk prostate cancer. Int J

Radiat Oncol Biol Phys 2012;84:1172-8. doi: 10.1016/j.

ijrobp.2012.02.049.

Pollack A, Hanlon AL, Horwitz EM, et al. Dosimetry

and preliminary acute toxicity in the first 100 men treated

for prostate cancer on a randomized hypofractionation

dose escalation trial. Int J Radiat Oncol Biol Phys

;64:518-26.

Pollack A, Walker G, Buyyounouski M, et al. Five year

results of a randomized external beam radiotherapy

hypofractionation trial for prostate cancer. Int J Radiat

Oncol Biol Phys 2011;81(Suppl. 2):S1

Kuban D, N.-G. GM, Hamblin L, et al. Preliminary

report of a randomized dose escalation trial for prostate

cancer using hypofractionation. Int J Radiat Oncol Biol

Phys 2010;78(Suppl. 3):S58-S59.

Katz A, Kang J. Stereotactic body radiation therapy for

low, intermediate and high risk prostate cancer: disease

control and quality of life at 6 years. Int J Radiat Oncol

Biol Phys 2013;87:524-5.

Loblaw A, Cheung P, D’Alimonte L, et al. Prostate

stereotactic ablative body radiotherapy using a

standard linear accelerator: toxicity, biochemical, and

pathological outcomes. Radiother Oncol 2013;107:153-

doi: 10.1016/j.radonc.2013.03.022.

Alicikus ZA, Yamada Y, Zhang Z, et al. Ten year

outcomes of high dose intensity modulated radiotherapy

for localized prostate cancer. Cancer 2011;117:1429-

doi: 10.1002/cncr.25467.

Chen LN, Suy S, Wang H, et al. Patient reported urinary

incontinence following stereotactic body radiation

therapy for clinically localized prostate cancer. Radiat

Oncol 2014;9:148. doi: 10.1186/1748-717X-9-148.




Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.